Chugai Pharmaceutical Overview
- Year Founded
-
1925
- Status
-
Public
- Employees
-
7,872
- Stock Symbol
-
4519
- Investments
-
9
- Share Price
-
$44.91
- (As of Friday Closing)
Chugai Pharmaceutical General Information
Description
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
Contact Information
Website
www.chugai-pharm.co.jpCorporate Office
- Nihonbashi Mitsui Tower (Reception 12th Floor)
- 1-1 Nihonbashi-Muromachi 2-chome, Chuo-ku
- Tokyo, 103-8324
- Japan
Corporate Office
- Nihonbashi Mitsui Tower (Reception 12th Floor)
- 1-1 Nihonbashi-Muromachi 2-chome, Chuo-ku
- Tokyo, 103-8324
- Japan
Chugai Pharmaceutical Stock Performance
As of 13-Nov-2026, Chugai Pharmaceutical’s stock price is $44.91. Its current market cap is $73.9B with 1.65B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $44.91 | $44.75 | $37.82 - $68.63 | $73.9B | 1.65B | 3.04M | $1.94 |
Chugai Pharmaceutical Financials Summary
As of 30-Sep-2026, Chugai Pharmaceutical has a trailing 12-month revenue of $8.99B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 58,959,345 | 81,280,023 | 67,588,195 | 57,716,393 |
| Revenue | 8,986,789 | 8,404,896 | 7,729,441 | 7,909,509 |
| EBITDA | 4,471,674 | 3,995,613 | 3,585,573 | 3,158,830 |
| Net Income | 3,200,533 | 2,899,839 | 2,557,420 | 2,316,358 |
| Total Assets | 15,083,091 | 15,781,130 | 14,063,361 | 13,703,092 |
| Total Debt | 0 | 0 | 0 | 0 |
Chugai Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Chugai Pharmaceutical Comparisons
Industry
Financing
Details
Chugai Pharmaceutical Competitors (26)
One of Chugai Pharmaceutical’s 26 competitors is Novartis, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novartis | Corporation | Basel, Switzerland | ||||
| Lilly USA | Corporation | Indianapolis, IN | ||||
| Torrent Pharmaceuticals | Corporation | Ahmedabad, India | ||||
| Cipla | Corporation | Mumbai, India | ||||
| Biocon | Formerly PE-Backed | Bengaluru, India |
Chugai Pharmaceutical Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Chugai Pharmaceutical Patents
Chugai Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2026176286-A | Anti-ctla-4 antibody and its use | Pending | 30-Jul-2026 | ||
| US-20260360497-A1 | Apparatus, method, and program for determining a dose of an antibody drug | Pending | 09-May-2025 | ||
| WO-2026230487-A1 | Pharmaceutical composition for treating or preventing ras wild-type cancer | Pending | 28-Apr-2025 | ||
| WO-2026225633-A2 | Heteromultimers of polypeptides containing fc region and drug conjugates thereof, and methods for producing the same | Pending | 25-Apr-2025 | ||
| WO-2026220989-A1 | Pharmaceutical composition for treating angioid streaks | Pending | 14-Apr-2025 |
Chugai Pharmaceutical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Chugai Pharmaceutical Investments & Acquisitions (9)
Chugai Pharmaceutical’s most recent deal was a Merger/Acquisition with Renalys. The deal was made on 01-Nov-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Renalys | 01-Nov-2025 | Merger/Acquisition | Drug Discovery | ||
| RegCell | 13-Nov-2020 | Early Stage VC | Biotechnology | ||
| AdipoSeeds | 16-Oct-2020 | Early Stage VC | Biotechnology | ||
| Preferred Networks | 26-Jul-2018 | Early Stage VC | Business/Productivity Software | ||
| RegCell | 10-May-2017 | Early Stage VC | Biotechnology |
Chugai Pharmaceutical ESG
Risk Overview
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Chugai Pharmaceutical Exits (2)
Chugai Pharmaceutical’s most recent exit was on 20-Dec-1989 from Gen-Probe. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Gen-Probe | 20-Dec-1989 | Completed |
|
||
| Genetics Institute | 01-Jan-1982 | Early Stage VC | Completed |
|
Chugai Pharmaceutical Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Chugai Venture Fund | Boston, MA | 2023 |
Chugai Pharmaceutical FAQs
-
When was Chugai Pharmaceutical founded?
Chugai Pharmaceutical was founded in 1925.
-
Where is Chugai Pharmaceutical headquartered?
Chugai Pharmaceutical is headquartered in Tokyo, Japan.
-
What is the size of Chugai Pharmaceutical?
Chugai Pharmaceutical has 7,872 total employees.
-
What industry is Chugai Pharmaceutical in?
Chugai Pharmaceutical’s primary industry is Pharmaceuticals.
-
Is Chugai Pharmaceutical a private or public company?
Chugai Pharmaceutical is a Public company.
-
What is Chugai Pharmaceutical’s stock symbol?
The ticker symbol for Chugai Pharmaceutical is 4519.
-
What is the current stock price of Chugai Pharmaceutical?
As of 13-Nov-2026 the stock price of Chugai Pharmaceutical is $44.91.
-
What is the current market cap of Chugai Pharmaceutical?
The current market capitalization of Chugai Pharmaceutical is $73.9B.
-
What is Chugai Pharmaceutical’s current revenue?
The trailing twelve month revenue for Chugai Pharmaceutical is $8.99B.
-
Who are Chugai Pharmaceutical’s competitors?
Novartis, Lilly USA, Torrent Pharmaceuticals, Cipla, and Biocon are some of the 26 competitors of Chugai Pharmaceutical.
-
What is Chugai Pharmaceutical’s annual earnings per share (EPS)?
Chugai Pharmaceutical’s EPS for 12 months was $1.94.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
